Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $9
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $9.
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $9.